June 4, 2017 Data from two phase II studies, the CheckMate 204 trial and the Anti-PD1 Brain Collaboration (ABC) trial, lend support to combined use of nivolumab and ipilimumab to yield responses in melanoma that has metastasized to the brain. Results from these studies, reported during the Melanoma/Skin Cancers Oral Abstract Session on June...
Pro zobrazení tohoto obsahu je třeba být přihlášen.